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Abstract
Background: We examined whether differences in tumor DNA methylation were associated with more aggressive
hormone receptor-negative breast cancer in an ethnically diverse group of patients in the Breast Cancer Care in
Chicago (BCCC) study and using data from The Cancer Genome Atlas (TCGA).
Results: DNA was extracted from formalin-fixed, paraffin-embedded samples on 75 patients (21 White, 31 African-
American, and 23 Hispanic) (training dataset) enrolled in the BCCC. Hormone receptor status was defined as
negative if tumors were negative for both estrogen and progesterone (ER/PR) receptors (N = 22/75). DNA
methylation was analyzed at 1505 CpG sites within 807 gene promoters using the Illumina GoldenGate assay.
Differential DNA methylation as a predictor of hormone receptor status was tested while controlling for false
discovery rate and assigned to the gene closest to the respective CpG site. Next, those genes that predicted ER/
PR status were validated using TCGA data with respect to DNA methylation (validation dataset), and correlations
between CpG methylation and gene expression were examined. In the training dataset, 5.7 % of promoter mean
methylation values (46/807) were associated with receptor status at P < 0.05; for 88 % of these (38/46), hypermethylation
was associated with receptor-positive disease. Hypermethylation for FZD9, MME, BCAP31, HDAC9, PAX6, SCGB3A1, PDGFRA,
IGFBP3, and PTGS2 genes most strongly predicted receptor-positive disease. Twenty-one of 24 predictor genes from the
training dataset were confirmed in the validation dataset. The level of DNA methylation at 19 out 22 genes, for which
gene expression data were available, was associated with gene activity.
Conclusions: Higher levels of promoter methylation strongly correlate with hormone receptor positive status of breast
tumors. For most of the genes identified in our training dataset as ER/PR receptor status predictors, DNA methylation
correlated with stable gene expression level. The predictors performed well when evaluated on independent set of
samples, with different racioethnic distribution, thus providing evidence that this set of DNA methylation biomarkers will
likely generalize to prospective patient samples.
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Background
Breast cancer has traditionally been described by histo-
pathological staging based on size, degree of invasiveness,
and lymph node metastasis and by immunochemical ana-
lysis of the epidermal growth factor receptor HER2 and the
estrogen (ER) and progesterone (PR) receptors. Recently,
there has been an increased awareness of the potential
influence of socioeconomic and psychosocial factors
on breast cancer aggressiveness characteristics [1–5].
One mechanism by which these processes might exert
their effects on activity of breast cancer genes is
through epigenetic alterations, including DNA methy-
lation. Therefore, addition of classification based on
DNA methylation and gene expression might improve
prognostic prediction to therapeutic response or
survival.
Previous studies using established cancer cell models
showed that tumor evolution includes genome-wide loss
of DNA methylation (hypomethylation) as well as
increase in promoter methylation at CpG islands
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(promoter hypermethylation) [6]. Genes involved in spe-
cific biological pathways have been recognized to be
methylated at their promoters in various types of cancer,
including breast cancer [7]. Distinctive patterns of pro-
moter methylation have been reported previously for
ER/PR-positive versus ER/PR-negative tumors [8–10].
ER/PR-negative tumors are of particular interest because
they tend to be the most aggressive form and lack tar-
gets for hormone therapy. Therefore, these new DNA
methylation-based characteristics had a potential to con-
tribute prognostic value in breast cancer management.
Prior studies using panels of DNA methylation markers,
however, are plagued by lack of reproducibility, in part
because these studies tend to focus on the top-most per-
forming markers [11], as opposed to genome-wide asso-
ciation. The reproducibility was likely varied from study
to study due to random error associated with commonly
used small sample size. The prevalence of certain
markers in particular cohort populations was not taken
into account, as race and ethnicity were either not re-
ported or lacking Hispanic and African-American pa-
tient population [8–10, 12].
The aims of our analyses were (1) to identify a set of
gene DNA methylation markers predictive of ER/PR sta-
tus in a training dataset of invasive breast cancer
samples from an ethnically diverse patient cohort (the
Breast Cancer Care in Chicago (BCCC) study); (2) to
validate DNA methylation markers identified in the
training data using a different, publically available valid-
ation dataset; and (3) to associate these DNA methyla-
tion markers with corresponding gene expression
changes. Through this approach, our goal was to identify
and validate a set of gene methylation markers that may
play an etiologic role in breast cancer subtypes.
Results
The level of DNA methylation is higher in ER/PR-positive
tumors in the training dataset
We tested if associations can be drawn between the
levels of DNA methylation and hormone receptor ER/
PR status in an ethnically diverse patient cohort with in-
vasive breast cancer disease. The cohort included the
ER/PR-positive group with tumors that were either ER
or PR positive and the ER/PR-negative group with tu-
mors that were both ER and PR negative. Patients with
ER/PR-positive tumors were similar to patients with ER/
PR tumors with regard to age at diagnosis, race/ethni-
city, stage at diagnosis, and family history of breast
cancer (Table 1).
Table 1 Patient and tumor characteristics by hormone receptor status in the BCCC dataset
Total (N = 75) ER/PR positive
N % % P value (chi-square test)
Age at diagnosis 0.88
<50 20 27 75
50–59 20 27 70
60–79 35 47 69
Race/ethnicity 0.44
nH Black 31 41 65
nH White 21 28 81
Hispanic 23 31 70
Pathological stage 0.39
1 23 31 83
2 33 44 67
3 18 24 61
4 1 1 100
Histologic grade 0.10
Low 5 7 100
Moderate 31 42 77
High 38 51 61
1st degree familial breast cancer 0.25
None 50 68 68
Moderate 18 24 67
Strong (<50/multiple affected) 6 8 100
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The group of ER/PR-positive tumors had significantly
higher mean β values than the group of hormone-
negative tumors (Fig. 1a). The scatter plot analysis
showed that β values for many genes were shifted rela-
tive to the identity line (Fig. 1b). When the data were
adjusted for age, race, and ethnicity, higher DNA
methylation was still associated with ER/PR-positive
status across the genes studied. In age- and race/ethni-
city-adjusted logistic regressions models of receptor-
positive status against each gene mean methylation
value individually, two thirds of the 806 associations
were qualitatively positive (0.68; 95 % CI 0.66, 0.72)
(Table 2). This represented twice as many positive asso-
ciations compared with inverse associations (ratio of
positive to inverse associations = 2.2; 96 % CI 1.9, 2.6).
When restricting analyses to coefficients with P values
not exceeding 0.05, more than 80 % of the 46
remaining associations were positive associations (0.83;
95 % CI 0.70, 0.93). This represented nearly five times
as many positive associations compared with inverse
associations (ratio of positive to inverse associations = 4.8;
96 % CI 2.4, 13).
Association of ER/PR status with DNA methylation at
specific genes
In order to identify genes which promoter DNA methy-
lation is associated with hormone receptor status, we
conducted significance analysis of microarrays (SAM)
analysis. The top 25 genes that had higher levels of DNA
methylation associated with receptor-positive disease
(Table 3, left column) were selected for more detailed
analysis. Hypermethylation of FZD9, MME, RAB32,
BCAP31, HDAC9, PAX6, SCGB3A1, PDGFRA, IGFBP3,
PTGS2, and SRC were the strongest predictors of ER/
PR-positive disease in the training dataset. Notably, none
of the top performing 25 genes had positive associations
between methylation and ER/PR-negative disease. To re-
late the predicted value of the identified genes, we per-
formed hierarchical clustering of β values for all genes
on the platform. In contrast to the predictor genes, hier-
archical clustering of β values using the whole set of
GoldenGate genes was unable to group samples accord-
ing to the receptor status (Additional file 1: Figure S1).
DNA methylation at disease predictor genes in the
validation dataset
We examined whether the 25 predictive gene methyla-
tion markers identified through the BCCC study (train-
ing dataset) would predict hormone receptor status in
data from The Cancer Genome Atlas (TCGA) (valid-
ation dataset). Methylation data from TCGA represent a
much larger platform, with 27,578 probes corresponding
to 14,475 genes in total [12]. An ER/PR-specific DNA
methylation pattern was apparent in these data from
TCGA (Additional file 1: Figure S2). The prevalence of
ER/PR-positive disease in the TCGA validation dataset
Fig. 1 Distribution of DNA methylation between ER/PR-negative and ER/PR-positive samples in the training dataset (BCCC). a Box plot of mean β
values. The level of methylation at each CpG site was defined by β values. β values close to 0 indicated low level of DNA methylation, and β
values close to 1 indicated high level of DNA methylation. The next levels of analysis were conducted at the gene level. Mean β values were
averaged for all CpG sites on the array for each individual gene. Statistical significance of difference in β values for each gene between the two
groups was determined by ks and Wilcox tests. b Scatter plot analysis of mean β values
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Table 2 Number of associations between DNA methylation and hormone receptor-positive breast cancer in the BCCC dataset




% positiveb 95 % CI Ratioc 95 % CI
Training dataset (N = 807 genes)
All associations 806 548 258 68 (66, 72) 2.2 (1.9, 2.6)
Associations with P value ≤0.20 180 146 34 81 (75, 86) 4.3 (3.0, 6.4)
Associations with P value ≤0.05 46 38 8 83 (70, 93) 4.8 (2.4, 12.7)
aNumber of logistic regression coefficients involved in each analysis
bPercentage of coefficients that represent a positive association between methylation and hormone receptor-positive breast cancer.
cRatio of the number of positive divided by the number of negative associations
Table 3 Validation of genes with differential DNA methylation as predictors of hormone status from the Illumina BCCC (training
dataset) using TCGA (validation dataset)
Training dataset Validation dataset Correlation with expression
Gene Associationa SAM d scoreb Associationa SAM d scorec ρd P valued
FZD9 Positive 3.94 Positive 8.65 −0.44 1.4E−15
MME Positive 2.95 Positive 2.14 −0.13 2.1E−02
RAB32 Positive 2.70 Positivee 1.11 −0.27 1.4E−06
BCAP31 Positive 2.66 Positive 5.61 −0.28 4.9E−07
HDAC9 Positive 2.64 Positive 7.60 −0.15 8.5E−03
PAX6 Positive 2.64 Positive 4.56 −0.27 2.0E−06
SCGB3A1 Positive 2.53 Positive 9.51 −0.29 3.8E−07
PDGFRA Positive 2.52 Positive 2.09 −0.30 1.1E−07
IGFBP3 Positive 2.51 Positive 6.37 −0.22 1.1E−04
PTGS2 Positive 2.50 Positive 5.69 −0.30 5.2E−08
SRC Positive 2.50 Not-associated 0.00 NA NA
CHI3L2 Positive 2.45 Positive 2.65 −0.69 2.2E−44
PGR Positive 2.44 Positive 5.39 0.34 1.3E−09
TMPRSS4 Positive 2.43 NA NA NA NA
RASSF1 Positive 2.43 Positive 7.78 −0.05 4.2E−01
TBX1 Positive 2.43 Positive 4.62 −0.05 4.2E−01
PARP1 Positive 2.38 Positive 2.48 −0.12 2.0E−02
COL1A1 Positive 2.32 Positive 4.15 0.08 1.7E−01
SOX17 Positive 2.32 Positive 2.22 −0.13 5.7E−05
RUNX3 Positive 2.29 Positive 7.06 −0.13 2.0E−02
TES Positive 2.23 Positive 2.15 −0.45 2.6E−16
GPATC3 Positive 2.21 Positivee 0.17 NA NA
S100A2 Positive 2.21 Positive 9.32 −0.52 2.6E−22
MYH11 Positive 2.20 Positive 3.61 −0.10 8.0E−02
BMP2 Positive 2.19 Positive 4.66 −0.37 1.3E−11
NA gene was absent in the dataset
aIndicates whether gene hypermethylation was associated with increased likelihood of ER/PR-positive breast cancer versus ER/PR-negative breast
cancer (“Positive”)
bd scores from SAM analysis using Δ of 0.7 on the GoldenGate dataset
cd scores from SAM analysis using Δ of 3 on the TCGA dataset. In cases where several probes per gene were present, the data is shown for the probe with the
highest SAM d score
dPearson correlation coefficient between methylation and expression from TCGA and the corresponding P value
eNon-significant association
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(78 %, 239 of 306) (Table 4) was similar to that in our
training dataset (71 %, 53 of 75) (Table 1). We per-
formed analysis of the TCGA data similar to the BCCC
data (Additional file 1: Figure S3). In the validation
(TCGA) dataset, 2088 DNA methylation probes were
strongly associated (d value >3.5) with ER/PR status.
Multiple probes for IGFBP3 or PTGS2 showed similar
DNA methylation pattern (Additional file 1: Figure S4).
Other predictor genes such as RASSF1, however, had a
subset of probes that did not distinguish between ER/
PR-positive and ER/PR-negative disease. The number of
genes exhibiting hypermethylation in ER/PR-positive tu-
mors was five times larger than the number of genes
exhibiting hypermethylation in ER/PR-negative tumors.
The BCCC dataset and the TCGA dataset were gener-
ated using different high-throughput platforms, with dis-
tinct probe design. Matching of the features from
different platforms can be approached in different ways.
When we matched the DNA methylation data at the
gene level, associations between methylation and ER/PR
status observed in the training dataset were generally
reproduced in the validation dataset (Fig. 2). Despite the
differences between the two platforms and patient co-
horts, strong correlations between DNA methylation
level and ER/PR status were observed for 21 out of the
24 gene methylation markers identified in the training
dataset with methylation data in the validation dataset
(Table 3); 17 were identified as predictors in the valid-
ation dataset based on t tests (Fig. 2 and Additional file 1:
Table S1). These results revealed a high degree of
consistency between the BCCC dataset and the validation
TCGA dataset.
DNA methylation at predictor genes correlates with gene
expression level
Within the TCGA (validation) dataset, both DNA
methylation and gene expression data were available for
a total of 12,197 genes. Consistent with the generally in-
hibitory effect of DNA methylation on gene activity,
DNA methylation was generally inversely correlated with
messenger RNA (mRNA) expression regardless of ER/
PR status (Additional file 2: Table S2, P value <0.05 in
Additional file 1: Figure S5). The number of genes for
which expression was significantly inversely correlated
with DNA methylation was twofold higher among ER/
PR-positive than among ER/PR-negative tumors (5649
versus 2771, respectively, P value <0.05 in Fig. 3a), sug-
gesting that ER/PR-positive tumors have more stable
level of expression at genes experiencing DNA methyla-
tion than ER/PR-negative tumors.
Many of the gene methylation markers that predicted
of ER/PR status in the training dataset of 75 samples
showed an inverse correlation between DNA methylation
and gene expression level when analyzed in sets of 75
randomly assembled TCGA samples (Additional file 1:
Figure S6). Regardless of whether we used DNA methy-
lation data from the training or the validation dataset,
an inverse correlation was common for gene methylation
markers that were predictors of ER/PR status (compare
Fig. 3b, c, also see Additional file 1: Figure S7). Highly
significant inverse correlations were observed for
FZD9, HDAC9, PAX6, PDGFRA, S100A2, and BMP2
genes, suggesting that DNA methylation at these CpG
sites results in stable changes in gene expression. A
positive correlation between DNA methylation and ex-
pression was found for one gene (i.e., PGR), suggesting
that DNA methylation at the CpG sites within the PGR
gene that were analyzed are not relevant to regulation
of promoter activity. Sample level data showed that the
predictor genes differ in the absolute level and robust-
ness of changes in gene expression between the ER/PR-
positive and ER/PR-negative groups (Fig. 3c). Our re-
sults suggest that hormone status correlates with DNA
methylation status and with the activity of the identi-
fied set of genes.
Discussion
In a training dataset of newly diagnosed breast can-
cer patients, we observed a general tendency for
higher levels of DNA methylation to be associated
with ER/PR-positive disease, and we identified a set
of predictor genes for which hypermethylation was
highly significantly associated with ER/PR-positive
Table 4 Patient and tumor characteristics by hormone receptor
status in the TCGA dataset
Total (N = 306) ER/PR positive
N % % P value
(chi-square test)
Age at diagnosis 0.008
<50 72 24 68
50–59 79 26 73
60–79 155 51 85
Race/ethnicity 0.001
nH White 182 59 77
nH Black 22 7 59
Hispanic 1 0 100
Asian 21 7 57
Unknown 80 26 91
Pathological stage 0.271
1 55 18 82
2 180 59 84
3 51 17 74
4 9 3 80
Missing 11 4 100
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disease. The vast majority of the predictor genes
were confirmed in a validation dataset despite the
fact that the methylation data from the validation
dataset relied on a mostly different set of probes
within the same 24 genes. Finally, increased methyla-
tion was associated with reduced expression for the
vast majority of gene methylation markers, suggest-
ing that we had identified a reproducible set of
genes whose methylation might play an etiologic role
in breast cancer subtypes.
Differential DNA methylation according to ER/PR sta-
tus has previously been observed in breast cancer in
both genome-wide studies [8–10, 12] and in studies of
individual genes [13, 14]. In contrast, there was only a
modest association of DNA methylation with HER2-
positive status [12]. A large study of 466 breast cancers
found that basal-like cancers which were 90 % ER/PR
negative had a tendency to display hypomethylation,
while luminal B (ER/PR-positive) breast cancers had a
tendency to display hypermethylation [12]. The luminal
Fig. 2 Training (BCCC) and validation (TCGA) datasets stratified based on DNA methylation data for disease predictor genes. a Sample level data
for DNA methylation (GoldenGate) in the BCCC dataset. Results of SAM-supervised classification of ER/PR status from β values are shown. β values
for disease predictors (one probe per gene listed in Table 3) are presented as a heat map. Data are shown grouped for hormone receptor-negative
samples (N = 22) and hormone receptor-positive samples (N = 53). P values from the t test for the difference between ER/PR-negative and
ER/PR-positive disease (Additional file 1: Table S1) are presented on the right. b Sample level data for DNA methylation in the TCGA. Mean β
values (when multiple probes were present) are reported for Table 3 genes, stratifying samples according to ER/PR status. P values from the
t test are shown on the right
Fig. 3 Correlation of DNA methylation with the level of gene expression in the validation dataset (TCGA). a Significance of the correlation between
the level of DNA methylation and expression for each gene as determined by Pearson correlation coefficient (PCC). The correlation test was run for
all samples, only ER/PR-negative samples, or only ER/PR-positive samples. b Correlation test (methylation versus expression) for predictors
(Table 3). c Sample level data for gene expression of predictors (Table 3). Data is presented for 22 ER/PR-negative tumors and 53 ER/PR-positive tumors.
The PCC across the BCCC samples and TCGA samples (methylation versus expression) is shown on the right
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B group had a low rate of mutations, in contrast to the
group with hypomethylation that had p53 mutations.
The characteristic hypermethylation of CpG islands
related to ER/PR-positive breast tumors, which was
termed “breast CpG island methylator phenotype”
(B-CIMP), was first reported in 2011 [15]. The
phenomenon of methylator phenotype was associated with
low risk of metastasis and high rates of survival independ-
ently of known breast cancer characteristics. This result is
consistent with the finding presented here that DNA
methylation was generally associated with less aggressive,
ER/PR-positive breast cancer.
The predictor genes that were differentially methylated
according to ER/PR status were also differentially
expressed. Loss of DNA methylation is not a prerequisite
of increase in gene activity [16], and genomic regions
that are hypomethylated in breast cancer cells compared
to normal mammary epithelial cells do not necessary ex-
hibit an increase in expression [17]. DNA hypomethyla-
tion occurs primarily in the form of partially methylated
domains, displaying allelic DNA methylation, where one
allele is DNA methylated while the second allele exhibits
histone methylations H3K9me3 or H3K27me3 [17]. Be-
cause these histone modifications support the formation
of repressive chromatin, loss of DNA methylation at one
allele while retaining H3K9me3 or H3K27me3 at an-
other allele fails to activate gene expression. On another
hand, acquisition of DNA methylation at a single allele
may have an effect on gene activity by limiting chroma-
tin accessibility and transcription factor binding even in
the absence of repressive histone modifications at an-
other allele. The analysis that we report in this paper
does not address the exact process through which DNA
methylation might contribute to the repression of gene
expression.
Our study yielded 24 disease predictors, which all have
been linked to cancers in previous studies. When ar-
ranged in the order of significance (i.e., d value) from
the top to the bottom genes in the list, the top gene is a
receptor for Wnt signaling, frizzled class receptor 9
(FZD9). Hypermethylation of FZD9 has been previously
shown to be associated with ER+ tumors [8, 10]. Hyper-
methylation of FZD9 correlates with transcriptional re-
pression and is an independent predictor of poor
prognosis for patients with acute myeloid leukemia
(AML) [18, 19]. The bottom gene in the list encodes
Bone Morphogenetic Protein 2 (BMP2). Promoter DNA
methylation of BMP2 contributes to drug resistance in
breast cancer [20]. Another most commonly inactivated
gene in various cancers, Ras association domain-
containing protein 1, RASSF1, undergoes either DNA
methylation or chromosomal deletion in breast cancer
[21]. In patients with chromosome deletion of FZD9 or
RASSF1, aberrant methylation of the remaining allele
was associated with the poorest clinical outcome [19, 21],
indicating their functional contribution.
If developed as diagnostic tool in breast cancer, DNA
methylation has certain advantages over other epigenetic
biomarkers. DNA methylation pattern is preserved
under harsh conditions and requires small amount of
the sample, which is important in clinical practice,
whereas microRNAs and histone modifications require
robust high-quality material. In addition, DNA methyla-
tion markers may be detectable in plasma providing for
development of non-invasive techniques for early detec-
tion and follow-up of breast cancer. For example, aber-
rant DNA methylation of SOX17 has been identified not
only in tumor tissue but also in plasma DNA [22], and
SOX17 appears to be hypermethylated in luminal B tu-
mors, but hypomethylated in basal-like tumors [23].
Genes such as SOX17 thus could be used as a prognostic
biomarker to identify patients at risk of developing me-
tastasis or recurrence.
There are at least two other alternative explanations
for the observed associations of gene DNA methylation
with hormone receptor status in our study. First, specific
methylation patterns may arise in tumors with different
cell-type of origin, in which case, methylation might not
be an etiologic driver of subtype but rather a marker of
subtype. Second, other molecular events such as histone
modifications associated with ER/PR may play an active
role in dictating DNA methylation level, either globally
or at specific genes. Traditionally, prediction of breast
cancer survival has made use of ER/PR status. Recent ef-
fort towards integrated view of epigenomic features and
transcriptome has provided important insights into
population-based molecular subgrouping in several can-
cer types [24]. Defining such subgrouping in breast can-
cer and focusing further analysis on representative
numbers from groups stratified by predictor genes will
help to link ethnic and socioeconomic factors to etiology
of ER/PR-positive and ER/PR-negative disease.
Conclusions
We identified a set of genes in a genome-wide study
whose DNA methylation status predicted ER/PR status
in training dataset as well as in a validation dataset from
TCGA. The patient cohorts were different in racioethnic
distribution but nevertheless displayed the same pre-
dictor genes. Moreover, aberrant methylation for many
of the genes identified in the present study has been
found in breast or other cancers in prior studies, indicat-
ing their potential use as biomarkers. Increased methyla-
tion was associated with reduced expression for the vast
majority of these genes, suggesting that it might play an
etiologic role in breast cancer subtypes and may provide
insights into biological pathways associated with tumors
of particular hormone receptor status.
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Methods
Training dataset
Formalin-fixed, paraffin-embedded (FFPE) tumor sam-
ples came from the Breast Cancer Care in Chicago
(BCCC) study which has been described elsewhere [25].
The protocol for conducting this study has been ap-
proved by the University of Illinois at Chicago Institu-
tional Review Board, and details on the consent process
have been published [26]. Association of clinicopatho-
logical features with ER/PR status in the BCCC dataset
was determined by chi-square test, and the P values are
presented in Table 1. Copies of pathology reports and
the corresponding set of hematoxylin and eosin (H&E)-
stained slides were requested from the pathology depart-
ment at each diagnosing institution, and a single path-
ologist selected tumor blocks representative of the
tumor. Two recuts (at 4 μm each) were made from each
selected block for H&E staining. The recuts were then
examined in order to identify invasive components of
the sample, and areas were marked according to tissue
component. Cores of invasive tissue (2 mm in diameter)
were obtained from the marked areas.
DNA extraction was performed by adding to each
core 100 μl xylene. After the incubation with gentle
shaking for 5 min, supernatant was removed by centri-
fugation at 14,000g to remove the paraffin. The
process was repeated two more times. The tissue was
then weighted and 2–4-mg tissue was used for DNA
extraction using Gentra Puregene kit (QIAGEN). All
tissues were homogenized after adding cell lysis solu-
tion, proteinase K, and overnight incubation. The ex-
tracted DNA was measured by NanoDrop and
normalized at 50 ng/μl concentration. Bisulfite con-
version was performed on 500 ng of extracted DNA
using EZ DNA methylation kit (Cat # D5001, Zymo
Research, Irvine, CA) according to the manufacturer’s
instructions. As the result of conversion, unmethy-
lated cytosine residues were converted to uracils. The
converted DNA was eluted in 10 μl M-Elution buffer
provided in the kit. DNA methylation assays were per-
formed using 5 μl bisulfite-converted DNA in Illumi-
na’s GoldenGate Assay for Methylation as per
Illumina’s protocol. The converted DNA was biotinyl-
ated, and the allele-specific oligos were added (for
methylated and unmethylated sequence). Unhybri-
dized oligos were washed away, and hybridized oligos
were enriched by PCR and hybridized to Sentrix Array
Matrix Universal Probe Set 7A, 1536 Bead Types. Im-
aging was performed in the Bead Array Reader. The
raw data was processed by the BeadStudio Methyla-
tion Module to generate β values. Eighty tumor sam-
ples were assayed, from which 75 were from patients
that had information on ER/PR status, and these 75
samples were subjected to downstream analysis.
Methylation assay using the GoldenGate platform
The GoldenGate Assay for Methylation (Illumina, San
Diego, CA) is a high-throughput bisulfite- and ligation-
based assay to detect DNA methylation from bisulfite-
converted genomic DNA. The GoldenGate Methylation
Cancer Panel I spans 1505 CpG loci selected from 807
genes. Each gene is represented by either one (28.6 %),
two (57.3 %), or three and more (14.1 %) CpG sites. Ap-
proximately two thirds of analyzed CpG sites are con-
tained within CpG islands (10). Each gene was
represented by up to five CpG sites that were located in
the promoter region. Genes included tumor suppressor
genes, oncogenes, genes involved in DNA repair, cell
cycle control, differentiation, and apoptosis. Information
on genes contained in the GoldenGate Cancer Panel 1
can be found in a Gene Annotation Data File (available
at http://support.illumina.com/downloads/goldengate_-
methylation_cancer_panel_product_files.html), including
gene identification numbers, symbols, and synonyms.
Mean gene methylation and receptor status
We modeled using logistic regression analysis each of
the 807 mean gene methylation values as a predictor of
ER/PR status (either positive versus both negative) one
at a time while adjusting for age and race/ethnicity (nH
White as the referent, nH Black, and Hispanic). The
resulting logistic coefficients for methylation variables
and their corresponding P values were assembled. We
then dichotomized coefficients into those representing a
qualitatively inverse association and those representing a
qualitatively positive association of higher methylation
with ER/PR-positive breast cancer. The percentage of as-
sociations that were positive, along with the ratio of the
number of positive divided by the number of negative
associations, was estimated along with 95 % confidence
intervals using bootstrapped bias-correction procedures
based on 1000 replications. In addition, to assess
whether or not difference between DNA methylation
was significantly different between ER/PR-positive and
ER/PR-negative groups, two-sided t tests were con-
ducted using the β value of each gene across the samples
in these two groups.
Validation dataset (TCGA) and HM27 platform
Association of clinicopathological features with ER/PR sta-
tus in the TCGA dataset was determined by chi-square test,
and the P values are presented in Table 4. DNA methyla-
tion and expression data archived within The Cancer Gen-
ome Atlas (TCGA) have been previously described [12]
and were downloaded from the TCGA Data Portal website
(http://tcga-data.nci.nih.gov/tcga/). We identified 306
receptor-positive and receptor-negative breast tumors from
TCGA with data based on the Illumina Infinium DNA
methylation platform, HumanMethylation27 (HM27)
Benevolenskaya et al. Clinical Epigenetics  (2016) 8:17 Page 8 of 10
BeadChip (Illumina). The HM27 BeadChip contains 27,578
CpG sites in the proximity of transcription start sites for
14,475 genes in the NCBI Genome Build 36. The genomic
locations and sequences for probes on the array were
downloaded from the TCGA Data Portal. There were 720
genes in the HM27 data that overlapped with the probes
from the GoldenGate. The TCGA dataset contains only a
few specific probes from the GoldenGate; therefore, direct
comparison at the probe level was not feasible between
these two platforms. Thus, the validation dataset of β values
was collected for all CpG sites corresponding to the genes
defined as predictors in training dataset (Table 3). From 25
predictor genes identified with GoldenGate, TCGA con-
tained data for 24 of these. Tumors from the TCGA dataset
were also analyzed for gene expression; these data were
generated on Agilent custom 244K whole genome
microarrays.
Using significance analysis of microarrays for association
of differential DNA methylation to hormone receptor
status
For both the training (BCCC) and validation (TCGA)
datasets, the level of methylation at each CpG site was
defined by a β value, with 0 indicating 0 % DNA methy-
lation and 1 indicating 100 % DNA methylation. All β
values for CpG sites that annotated to the same gene
were averaged, and each mean gene methylation variable
was modeled as a predictor of ER/PR status. Analysis
was performed using significance analysis of microarrays
(SAM) algorithm (http://statweb.stanford.edu/~tibs/
SAM/). SAM uses permutations of the data in order to
identify a threshold that can be used to control the false
discovery rate (FDR). The following parameters were
used: S0 parameters were selected using Tusher et al.
method and K-nearest neighbor imputer was used with
10 neighbors.
mRNA gene expression profiling dataset (TCGA)
Tumors from the TCGA dataset were analyzed for gene
expression using data generated on Agilent custom
244K whole genome microarrays. For correlation ana-
lyses, genes for which there were no expression values
recorded were removed from the analysis. Thus, 12,197
genes were available to analyze the correlation between
methylation and expression, including 720 of the 807
genes of the GoldenGate platform. Kolmogorov-Smirnov
(ks) tests, Wilcox tests, and Pearson correlation coeffi-
cients (PCC) were calculated using R/Bioconductor soft-
ware (http://www.bioconductor.org). The heat maps
were generated using GiTools [27].
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